The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Lysopadol 17.86 mg/ml oromucosal spray, solution

17.86 milligram(s)/millilitre Oromucosal spray, solution

Sanofi-Aventis Ireland Limited T/A SANOFIPA0540/186/002

Main Information

Trade NameLysopadol 17.86 mg/ml oromucosal spray, solution
Active SubstancesAMBROXOL HYDROCHLORIDE
Strength17.86 milligram(s)/millilitre
Dosage FormOromucosal spray, solution
Licence HolderSanofi-Aventis Ireland Limited T/A SANOFI
Licence NumberPA0540/186/002

Group Information

ATC CodeR02AD Anesthetics, local

Status

Authorised/WithdrawnAuthorised
Licence Issued14/02/2014
Legal statusProduct not subject to medical prescription
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to the general public
Conditions of Licence
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back